PDS Biotechnology Publishes Promising Versamune® HPV Study Data

PDS Biotechnology ( (PDSB) ) has shared an update.

On May 22, 2025, PDS Biotechnology announced the publication of three abstracts on their Versamune® HPV studies, which will be presented at the 2025 American Society of Clinical Oncology Annual Meeting. The abstracts highlight positive extended follow-up data from the VERSATILE-002 trial, showing significant survival benefits for patients with HPV16-positive recurrent/metastatic head and neck cancer. The announcement underscores PDS Biotech’s confidence in their ongoing VERSATILE-003 trial, which aims to address the growing population of HPV16-positive patients, potentially impacting the company’s market position and offering new hope for stakeholders.

The most recent analyst rating on (PDSB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers, developing its targeted immunotherapy Versamune® HPV in combination with standard-of-care immune checkpoint inhibitors.

Average Trading Volume: 656,671

Technical Sentiment Signal: Sell

Current Market Cap: $74.51M

Find detailed analytics on PDSB stock on TipRanks’ Stock Analysis page.